報價延遲最少15分鐘:2025/05/12 10:22 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.29 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.21/-0.11
|
|
企業價值
872.30M
|
| 資產負債 |
|
每股賬面淨值
0.44
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
76.99M
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/12 10:22 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology. |